# OnCo record resminostat (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/resminostat/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "resminostat" ;
  schema:name "Resminostat"@en ;
  schema:alternateName "resminostat"@en, "resminostat mesilate"@en, "Kinselby"@en, "4SC-201"@en, "Kinselby" ;
  schema:description "Resminostat is an oral drug of the HDAC inhibitor class, proposed for advanced mycosis fungoides and Sézary syndrome, two cutaneous T-cell lymphomas. Europe's medicines committee said no to it in May 2025, so it is not authorised."@en ;
  schema:url <https://onco.cc/drugs/resminostat/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/kinselby> ;
  onco:tag "ema-register" ;
  onco:modality "Small-molecule HDAC inhibitor" ;
  onco:related <https://onco.cc/drugs/romidepsin/> ;
  onco:cancers <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/hdac/> ;
  onco:companies <https://onco.cc/companies/4sc/> .